272
Participants
Start Date
September 29, 2021
Primary Completion Date
August 25, 2022
Study Completion Date
November 22, 2022
LY3502970
Administered orally
Placebo
Administered orally
Szent Margit Rendelőintézet Nonprofit Kft, Budapest
Clinexpert Kft., Budapest
TRANTOR'99 Bt. Anyagcsere Centrum, Budapest
Bugát Pál Kórház, Gyöngyös
Debreceni Egyetem Klinikai Kozpont, Debrecen
Studium Egeszseghaz Kft, Kalocsa
DRC Gyógyszervizsgáló Központ, Balatonfüred
Kanizsai Dorottya Korhaz, Nagykanizsa
Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair, Pittsburgh
Capital Area Research, LLC, Camp Hill
National Clinical Research, Inc, Richmond
St. Vincent Hospital d/b/a Prevea Health, Green Bay
Lillestol Research, Fargo
StudyMetrix Research, City of Saint Peters
Intend Research, LLC, Norman
Dallas Diabetes Research Center, Dallas
Diabetes and Thyroid Center of Fort Worth, Fort Worth
Texas Diabetes & Endocrinology, P.A., Round Rock
Elite Clinical Trials, Blackfoot
Rocky Mountain Clinical Research, Idaho Falls
Valley Clinical Trials, Inc., Northridge
Anaheim Clinical Trials, LLC, Anaheim
John Muir Physician Network Research Center, Concord
Norcal Endocrinology & Internal Medicine, San Ramon
NorCal Medical Research, Inc, Greenbrae
Premier Research, Trenton
C-health Research, Calgary
Wharton Medical Clinic, Hamilton
Bluewater Clinical Research Group Inc., Sarnia
Centre Médical et Professionnel de l'Ouest de Portneuf, Saint-Marc-des-Carrieres
Alpha Recherche Clinique, Québec
ALPHA Recherche Clinique, Québec
Strazsahegy Medicina Bt., Budapest
Puerto Rico Medical Research, Ponce
Research and Cardiovascular Corp., Ponce
Eli Lilly and Company
INDUSTRY